As critical cell arrest modulators, the urine biomarkers IGFBP-7 and TIMP-2 are involved in the early phase of cellular stress and are used to predict AKI, especially moderate and severe AKI.95,144 In 2019, Kellum et al. published a guide for the clinical use of the [TIMP-2]* [IGFBP-7] biomarker to assess the risk of AKI in critical care.145 Recent evidence shows that these biomarkers may also predict adverse outcomes of AKI patients in the ICU.146,147 There are other potential biomarkers for AKI. The gene discussed is TIMP2; the disease is acute kidney injury.